Cellectar Biosciences, Inc. (CLRB)
NASDAQ: CLRB · Real-Time Price · USD
2.770
0.00 (0.00%)
Mar 6, 2026, 4:00 PM EST - Market closed
Cellectar Biosciences Stock Forecast
Stock Price Forecast
There have not been any analyst price target forecasts for Cellectar Biosciences in the last 12 months.
Price Target: n/a
Analyst Consensus: Hold
Analyst Ratings
According to 1 stock analyst, the rating for Cellectar Biosciences is "Hold". This means that the analyst believes this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 2 | 2 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | May 14, 2025 |
| Oppenheimer | Oppenheimer | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Dec 11, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $420 → $360 | Buy | Maintains | $420 → $360 | +12,896.39% | Nov 19, 2024 |
| Oppenheimer | Oppenheimer | Buy Reiterates $420 | Buy | Reiterates | $420 | +15,062.45% | Oct 11, 2024 |
| Roth MKM | Roth MKM | Strong Buy Maintains $600 → $840 | Strong Buy | Maintains | $600 → $840 | +30,224.91% | Mar 28, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
8.65M
EPS This Year
-7.67
from -8.35
EPS Next Year
-5.20
from -7.67
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | n/a | 8.9M | |||
| Avg | n/a | 8.7M | |||
| Low | n/a | 8.3M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -2.90 | -2.54 | |||
| Avg | -7.67 | -5.20 | |||
| Low | -16.18 | -6.76 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.